Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

近期，国睿科技股份有限公司接到子公司芜湖国睿兆伏电子有限公司（简称 国睿兆伏）通知，国睿兆伏投标的"GXLF 项目片放泵浦源"项目发布了评标结 果，国睿兆伏为该项目的中标候选人，该结果在中国工程物理研究院招投标信息 网（ztbxx.caep.ac.cn）上进行了公示，公示期为 2025 年 12 月 8 日至 2025 年 12 月 12 日。 本次项目招标人为中国工程物理研究院激光聚变研究中心，项目内容为根据 片放泵浦源功能及技术指标要求完成相应的工程设计、加工制造、安装集成与调 试、验收交付等工作。国睿兆伏对该项目的投标报价为人民币 76,000,000.00 元（柒仟陆佰万元整）。 证券代码：600562 证券简称：国睿科技 公告编号：2025-034 国睿科技股份有限公司 关于子公司项目预中标的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 国睿兆伏后续将在收到中标通知书后，履行合同签订等程序，敬请投资者注 意投资风险。 特此公告。 国睿科技股份有限公司董事会 2025 年 12 月 13 日 ...

本次项目招标人为中国工程物理研究院激光聚变研究中心，项目内容为根据片放泵浦源功能及技术指标 要求完成相应的工程设计、加工制造、安装集成与调试、验收交付等工作。国睿兆伏对该项目的投标报 价为人民币7600万元（柒仟陆佰万元整）。 格隆汇12月12日丨国睿科技(600562.SH)公布，近期，国睿科技股份有限公司接到子公司芜湖国睿兆伏 电子有限公司通知，国睿兆伏投标的"GXLF 项目片放泵浦源"项目发布了评标结果，国睿兆伏为该项目 的中标候选人，该结果在中国工程物理研究院招投标信息网上进行了公示，公示期为2025年12月8日至 2025年12月12日。 ...

格隆汇12月12日丨国睿科技(600562.SH)公告称，公司子公司芜湖国睿兆伏电子有限公司为"GXLF 项目 片放泵浦源"项目的中标候选人，投标报价为7600万元。该项目招标人为中物院激光聚变研究中心，主 要内容为片放泵浦源的工程设计、加工制造等。国睿兆伏将在收到中标通知书后，履行合同签订等程 序。 ...

格隆汇12月12日丨国睿科技(600562.SH)公布，近期，国睿科技股份有限公司接到子公司芜湖国睿兆伏 电子有限公司通知，国睿兆伏投标的"GXLF 项目片放泵浦源"项目发布了评标结果，国睿兆伏为该项目 的中标候选人，该结果在中国工程物理研究院招投标信息网上进行了公示，公示期为2025年12月8日至 2025年12月12日。 本次项目招标人为中国工程物理研究院激光聚变研究中心，项目内容为根据片放泵浦源功能及技术指标 要求完成相应的工程设计、加工制造、安装集成与调试、验收交付等工作。国睿兆伏对该项目的投标报 价为人民币7600万元（柒仟陆佰万元整）。 ...

每经AI快讯，12月12日，国睿科技（600562）(600562.SH)公告称，公司子公司芜湖国睿兆伏电子有限 公司为"GXLF项目片放泵浦源"项目的中标候选人，投标报价为7600万元。该项目招标人为中物院激光 聚变研究中心，主要内容为片放泵浦源的工程设计、加工制造等。国睿兆伏将在收到中标通知书后，履 行合同签订等程序。 ...

本次项目招标人为中国工程物理研究院激光聚变研究中心，项目内容为根据片放泵浦源功能及技术指标 要求完成相应的工程设计、加工制造、安装集成与调试、验收交付等工作。国睿兆伏对该项目的投标报 价为人民币7600万元。 国睿科技（600562）(600562.SH)发布公告，近期，国睿科技股份有限公司接到子公司芜湖国睿兆伏电 子有限公司(简称国睿兆伏)通知，国睿兆伏投标的"GXLF项目片放泵浦源"项目发布了评标结果，国睿 兆伏为该项目的中标候选人，该结果在中国工程物理研究院招投标信息网上进行了公示，公示期为2025 年12月8日至2025年12月12日。 ...

人民财讯12月12日电，国睿科技（600562）12月12日公告，子公司国睿兆伏成为"GXLF项目片放泵浦 源"项目的中标候选人，项目内容为根据片放泵浦源功能及技术指标要求完成相应的工程设计、加工制 造、安装集成与调试、验收交付等工作。国睿兆伏对该项目的投标报价为7600万元。 ...

本次项目招标人为中国工程物理研究院激光聚变研究中心，项目内容为根据片放泵浦源功能及技术指标 要求完成相应的工程设计、加工制造、安装集成与调试、验收交付等工作。国睿兆伏对该项目的投标报 价为人民币7600万元。 智通财经APP讯，国睿科技(600562.SH)发布公告，近期，国睿科技股份有限公司接到子公司芜湖国睿 兆伏电子有限公司(简称国睿兆伏)通知，国睿兆伏投标的"GXLF项目片放泵浦源"项目发布了评标结 果，国睿兆伏为该项目的中标候选人，该结果在中国工程物理研究院招投标信息网上进行了公示，公示 期为2025年12月8日至2025年12月12日。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司2025年5月13日召开2024年年度股东会，授权公司董事会于2025年上半年或第三季度，在符合相关 利润分配条件和分配计划的情况下,制定具体的2025年中期现金分红方案。公司2025年10月23日召开第 十届董事会第五次会议审议通过《2025年前三季度利润分配方案》。 二、分配方案 1.发放年度：2025年前三季度 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 本次利润分配以方案实施前的公司总股本1,241,857,840股为基数，每股派发现金红利0.097元（含税）， 共计派发现金红利120,460,210.48元。 三、相关日期 ■ 四、分配实施办法 1.实施办法 除公司自行发放对象外，其他股东的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上 海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派 ...